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Abstract Background: There is growing clinical interest
in thalidomide for the treatment of various disorders due
to its anti-inﬂammatory, immunomodulatory, and anti-
angiogenic properties. In numerous clinical trials tha-
lidomide is used as an adjunct to standard therapy.
Therefore, clinicians should be aware of all possible
drug–drug interactions that might occur with this drug.
P-glycoprotein (P-gp), a drug eﬄux transporter that is
expressed in many tissues, is the cause of several drug–
drug interactions. P-gp induction or inhibition can lead
to ineﬀective therapy or side-eﬀects. In this study, we
investigated thalidomide’s potential to cause drug–drug
interactions on the level of P-gp. Methods: LS180 cells
were incubated with thalidomide for 72 h in order to
determine P-gp induction using real-time RT-PCR. A
human leukaemia cell line over-expressing MDR1
(CCRF-CEM/MDR1) was used to measure uptake of
rhodamine 123, a P-gp substrate, in the presence of
thalidomide. Dose-dependent and bi-directional trans-
port of thalidomide through Caco-2 cell monolayers
was performed to assess site-directed permeability.
Transport rates were determined using HPLC including
chiral separation of the thalidomide enantiomers.
Results: Thalidomide did not induce P-gp expression in
LS180 cells. The uptake of rhodamine 123 in CCRF cells
over-expressing MDR1 was not inﬂuenced by co-incu-
bation with thalidomide. The transport through Caco-2
monolayers was linear and the permeability was similar
for both directions. No diﬀerences between the thalid-
omide enantiomers were observed. Conclusions: Our
study indicates that thalidomide is neither a substrate,
nor an inhibitor or an inducer of P-gp. Therefore, P-gp-
related drug–drug interactions with thalidomide are not
likely.
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Introduction
Thalidomide was widely used in Europe as a sedative-
hypnotic drug (Contergan) since 1956. In the early 1960s
it was withdrawn from the market due to its obvious
teratogenic eﬀects. Later, in 1965, it was reported to
show remarkable eﬃcacy against erythema nodosum
leprosum [1]. The recent renewed interest in thalidomide
is based on its potential to treat inﬂammatory and
autoimmune disorders and to its anti-angiogenic activity
[2]. Anti-inﬂammatory and immunomodulatory eﬀects
of thalidomide have been explained by a degradation of
mRNA encoding tumour necrosis factor-a (TNF-a) in
monocytes [3]. Furthermore, thalidomide seems to in-
hibit the production of the cancer-associated growth
factor interleukin-6 [4, 5] and the production of several
other cytokines [6]. Clinical applications of thalidomide
include aphthous ulcers, Behc¸et‘s syndrome, rheumatoid
arthritis, graft-versus-host disease, and inﬂammatory
bowel disease. In addition, malignant diseases such as
haematological cancers, prostate cancer, and renal-cell
carcinoma have been treated with thalidomide [7, 8].
Thalidomide (a-phthalidomidoglutarimide) is a neu-
tral racemic compound derived from glutamic acid. It is
applied in equimolar amounts of (+)-(R)- and ()-(S)-
enantiomers that rapidly interconvert at physiological
pH [9]. The parent compound undergoes spontaneous
hydrolysis in aqueous solution at pH 7, leading to twelve
hydrolysis products [10]. This non-enzymatic hydrolysis
is the main breakdown mechanism of thalidomide in
the body, whereas hepatic metabolism seems to play a
minor role [11]. Therefore, only low concentrations of
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5-hydroxythalidomide were detectable in a human study
[12]. Additionally, it was shown in vitro that thalidomide
is a poor substrate for cytochrome P-450 isoenzymes
and that it does not inhibit the metabolism of CYP-
speciﬁc substrates [13]. These results suggest that tha-
lidomide is not involved in clinically important drug–
drug interactions caused by an inhibition of cytochrome
P-450 metabolism.
However, interactions may also occur at the level of
drug transporters such as P-gp, the gene product of
MDR1 (ABCB1). P-gp is an eﬄux pump, located on the
apical membrane of cells. It actively extrudes a variety of
substances and presumably functions as a biological
barrier against xenobiotics and pathogens [14]. It is ex-
pressed in many tissues such as intestine, kidney, liver,
and blood brain barrier [15, 16]. Due to its broad sub-
strate speciﬁcity it limits the absorption of numerous
unrelated substances such as HIV drugs, anticancer
drugs, and endogenous compounds [17–19]. Therefore,
competition for substrate binding, inhibition or up-reg-
ulation of this transporter can lead to signiﬁcant changes
in the pharmacokinetics of P-gp substrates. Many cases
of drug–drug interactions on the basis of these mecha-
nisms have already been reported [20].
Due to its anti-angiogenic activity, thalidomide is
being tested in patients who suﬀer from various cancers
[21]. In tumour cells, P-gp is often over-expressed,
making them resistant to P-gp substrates [22]. Whether
thalidomide is also a substrate of this transporter could
therefore be of interest. Moreover, many drugs used in
cancer therapy such as actinomycin C, etoposide, te-
niposide, paclitaxel, docetaxel, and topotecan, as well as
glucocorticoids and morphine are P-gp substrates. The
co-administration of a potential inhibitor or inducer of
P-gp could inﬂuence the therapy due to the described
mechanisms.
Since thalidomide is mostly used as an adjuvant
therapy, clinicians should be aware of all possible
drug–drug interactions. So far, there is nothing known
about the aﬃnity of thalidomide to transporter pro-
teins such as P-gp. In this study, experiments were
performed to determine the eﬀect of thalidomide on
the function and expression of this clinically important
drug eﬄux transporter. This knowledge can help to
assess the risk of P-gp-related drug–drug interactions
during therapies where thalidomide is applied. More-
over, it might further elucidate the process of thalid-
omide absorption.
Materials and methods
Determination of MDR1 mRNA induction
with quantitative real-time RT-PCR
(+/)-Thalidomide and rifampicin (Sigma-Aldrich
Chemie GmbH, Schnelldorf, Germany) were dissolved
in dimethyl sulphoxide (DMSO). LS180 cell line (used
between passage 40 and 45) was purchased from ATCC
(Manassas, USA). Cells were cultured in Dulbecco’s
MEM with Glutamax-I, supplemented with 10% (v/v)
foetal calf serum, 1% non-essential amino acids, 1%
sodium pyruvate, and 50 lg/ml gentamycin. Cultures
were maintained in a humidiﬁed 37C incubator with a
5% carbon dioxide in air atmosphere. The cells were
seeded into six well plastic culture dishes (9.2 cm2/well)
and after they had reached conﬂuence they were treated
with 10 and 100 lM thalidomide and 10 lM rifampicin
for 72 h.
The stability of thalidomide in our cell culture media
at 37C was determined over a period of up to 4 hours.
The concentration decreased to 74, 53, and 18% after 1,
2, and 4 h, respectively (data not shown). Consequently,
in the incubation experiments we applied relatively high
thalidomide concentrations (10 and 100 lM) and the
medium was changed twice a day. Although we could
not exclude signiﬁcant degradation, this approach re-
ﬂects the clinical situation of oral thalidomide adminis-
tration, which is given two times a day.
At the end of the culture period, total RNA was ex-
tracted using the RNeasy Mini Kit (Qiagen, Hilden,
Germany). RNA was quantiﬁed with a GeneQuant
photometer (Pharmacia, Uppsala, Sweden). The purity
of the RNA preparations was high as demonstrated by
the 260/280 nm ratio (range 1.8–2.0). After DNaseI
digestion (Gibco, Life Technologies, Basel Switzerland)
1 lg of total RNA was reverse-transcribed by Super-
script (Gibco, Life Technologies, Basel, Switzerland)
according to the manufacturer’s protocol using random
hexamers as primers.
TaqMan analysis was carried out on a Gene Amp
5700 Sequence Detector (Applied Biosystems). PCR
conditions were 10 min, 95C followed by 40 cycles of
15 s, 95C and 1 min, 60C. Each TaqMan reaction
contained 25 ng of cDNA in a total volume of 25 lL
using TaqMan Universal PCR Mastermix (Applied
Biosystems). The concentrations of primers and probes
were 900 nM and 225 nM, respectively. They were de-
signed according to the guidelines of Applied Biosystems
with the help of the Primer Express 2.0 software (MDR1
forward primer: 5¢-CTGTATTGTTTGCCACCACGA-
3¢; MDR1 probe: 5¢-AAGCTGTCAAGGAAGCCAAT
GCCTATGACTT-3¢; MDR1 reverse primer: 5¢-AGGG
TGTCAAATTTATGAGGCAGT-3¢; GAPDH forward
primer 5¢-GGTGAAGGTCGGAGTCAACG-3¢; GA
PDH probe 5¢-CGCCTGGTCACCAGGGCTG C-3¢;
GAPDH reverse primer 5¢-ACCATGTAGTTGAGGT
CAA TGAAGG-3¢). Primers were synthesised by Invi-
trogen (Basel, Switzerland), probes by Eurogentec
(Seraing, Belgium). For absolute quantiﬁcation, we used
external standard curves. Standards were gene-speciﬁc
cDNA fragments that cover the TaqMan primer/probe
area. All samples were run in triplicates and RNA that
was not reverse-transcribed served as a negative control.
Results are expressed as ratios of MDR1 to GAPDH
expression.
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Rhodamine 123 uptake in CCRF-CEM/MDR1 cells
CCRF-CEM/MDR1 cells (human leukaemic T-lym-
phocytes over-expressing MDR1) were a gift from
Altana Pharma Ltd. (Konstanz, Germany). The cells
were grown in suspension and were cultured in RPMI
1640 medium with Glutamax-I, supplemented with
10% FCS and 50 lg/mL gentamycin. Cells were con-
tinuously cultured in the presence of 1 lg/ml vincristine
under 5% CO2/95% air atmosphere at 37C. One day
before the experiment, cells were grown in vincristine-
free medium.
Two million CCRF-CEM/MDR1 cells per millilitre
were pre-incubated at 37C for 10 min in the presence of
10, 100, and 300 lM thalidomide or 100 lM verapamil
(both Sigma-Aldrich Chemie, Schnelldorf, Germany),
followed by an incubation with additional 5 lM rho-
damine 123 (Molecular Probes, Eugene, OR). After
15 min, rhodamine 123 uptake was stopped by trans-
ferring samples to ice. Cells were washed three times in
the presence of the previously applied drug at 4C and
lysed in 1% Triton X-100. Aliquots were transferred
into Optiplate-96 plates (Packard, Zu¨rich, Switzerland)
and ﬂuorescence of the lysate was analysed with a
HTS 7000 Plus Bio Assay Reader (Perkin Elmer Ltd.,
Buckinghamshire, UK) with 485 nm excitation and
535 nm emission ﬁlters. Prior to the assay, possible
quenching of rhodamine 123 due to thalidomide or
verapamil was checked for all concentrations used in the
uptake experiment.
Transport of (±)-thalidomide across Caco-2 cell
monolayers
Caco-2 cells (used between passage 54 and 59) were
purchased from ATCC (Manassas, USA). They were
cultured in Dulbecco’s MEM with Glutamax-I, sup-
plemented with 10% foetal calf serum, 1% non-essen-
tial amino acids, 1% sodium pyruvate, and 50 lg/ml
gentamycin. Cells were seeded with a density of
6·104 cells/cm2 onto Snapwell polycarbonate mem-
brane ﬁlters (12 mm diameter, 0.4 lm pore size; Costar,
Cambridge, MA) and were cultured in standard six-well
cluster plates in a humidiﬁed 37C incubator with a 5%
Co2 in air atmosphere. The membranes with the cell
monolayer were placed into a side-by-side diﬀusion
chamber (Costar) 16 days after seeding. The experi-
ments were performed at 37C with sample volumes of
4 mL per compartment. Cells were washed twice and
equilibrated for 10 min with pre-heated transport buﬀer
[Hank’s balanced salt solution (HBSS) + 1 mM
pyruvate].
Bi-directional transport was initiated by adding
transport buﬀer containing 100 lM thalidomide to the
donor chamber (apical or basolateral side of the cell
monolayer). The transport buﬀer was removed from the
acceptor compartment after 5, 10, 15, and 30 min and
replaced with fresh buﬀer. For the investigation of dose-
dependent transport 10, 50, 100, and 250 lM thalido-
mide were added to the apical compartment. After
10 minutes the buﬀer in the basolateral compartment
was removed for analysis.
According to Eriksson et al. [23] the drawn samples
were instantly acidiﬁed with citrate buﬀer (pH 1.5) and
frozen until further processing. This approach prevents
interconversion and hydrolysis of thalidomide enantio-
mers. The paracellular marker ﬂuorescein isothiocyanate
dextran (FITC dextran, MW 4000, Sigma-Aldrich
Chemie GmbH, Schnelldorf, Germany) was used for
monitoring the monolayer integrity after each experi-
ment. FITC dextran transport was measured in a ﬂuo-
rescence reader (Perkin Elmer HTS Soft 7000 Plus).
Determination of thalidomide concentrations in the
transport buﬀer samples was performed in triplicates by
an enantioselective HPLC analysis. The HPLC system
(LaChrom) and the software (D-7000 HPLC system
manager) were from Merck Hitachi. The following
components were integrated into the HPLC system:
interface D-7000, diode array detector L-7455, column
oven L-7300, autosampler L-7200, pump L-7100. For
the separation of the thalidomide enantiomers, a chiral
column (Chiralcel OJ, 250·46 mm, Daicel Chemical
Industries) was used.
The temperature of the column was 40 C. The
mobile phase consisted of 65% ethanol and 35% hexane
with a ﬂow rate of 0.85 mL/min. Injection volume of the
samples was 80 lL. UV detection of the substances was
performed at a wavelength of 220 nm. (+)-Thalidomide
and ()-thalidomide were well separated with retention
times of 11.15 and 14.75 min, respectively. The standard
curves were linear (correlation coeﬃcients > 0.999) in
the concentration range of 20–2.0 lg/mL (correspond-
ing to 77.45 nM–7.745 lM). The lower limit of quanti-
ﬁcation was 20 ng/mL (signal-to-noise ratio >5) for
both enantiomers. Precision and accuracy of the method
were determined at 0.02, 0.5, and 2 lg/mL (corre-
sponding to 77.45 nM, 1.94 lM, and 7.745 lM,
respectively). The precision (coeﬃcient of variation) and
accuracy (deviation of the true value from the mean
value) were below 15% for all concentrations (n=5). All
response values were based on the ratio of peak height of
the thalidomide enantiomers to that of anthracene.
Anthracene was used as internal standard with a ﬁnal
concentration of 2 lg/mL.
After addition of 5.0 mL of extraction medium
[dichloromethane:hexane 1:1(v/v)], the samples were
shaken for 20 min. The organic layers were separated by
centrifugation (3000 rpm, 0C, 10 min) and then trans-
ferred to another glass tube. The solvent was evaporated
under a N2 stream at 40C for 12 min. The residue was
re-dissolved in 200 lL of methanol by means of vor-
texing and ultra-sonic. The solution was then ﬁltered
through a 0.2 lm ﬁlter and 80 lL was injected into the
HPLC system.
For the investigation of bi-directional (apical-to-
basolateral and basolateral-to-apical) transport, the
apparent permeability values (Papp) were calculated as:
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Papp ¼ DQ=Dt  1=A 1=C0:
Initial slope, D Q/D t, was determined by plotting the
amount of transported thalidomide enantiomer (micro-
moles) as a function of time (s). The slope of the line was
calculated using linear regression. Time points were 5,
10, 15, and 30 min. A is the surface of the ﬁlter (cm2) and
C0 is the thalidomide concentration (lM) in the donor
compartment.
For the determination of dose-dependent transport,
the amount of each thalidomide enantiomer (nanomo-
les) in the basolateral compartment after 10 min was
plotted against the applied concentration in the apical
compartment. The correlation coeﬃcients were deter-
mined by linear regression.
Results
In LS180 cells, thalidomide treatment had no eﬀect on
MDR1 expression. Incubation with 10 and 100 lM
thalidomide for 72 h did not change the MDR1 mRNA
transcript number compared to control (Fig. 1). Rif-
ampicin, as a positive control for MDR1 induction,
increased the expression 2.5-fold. The expression of the
housekeeping gene GAPDH was not altered under any
of the treatments (data not shown).
The uptake of the P-gp substrate rhodamine 123 in
CCRF-CEM/MDR1 cells was not signiﬁcantly changed
by thalidomide treatment compared to control (Fig. 2).
Thalidomide concentrations of 10, 100 and 300 lM did
not inﬂuence P-gp function, whereas verapamil showed
strong P-gp inhibition as the intracellular ﬂuorescence of
rhodamine increased about ﬁvefold. At all applied
concentrations, thalidomide and verapamil exhibited no
quenching regarding the ﬂuorescence of rhodamine 123
(data not shown).
The bi-directional transport of 100 lM thalidomide
across Caco-2 cell monolayers indicates that the per-
meability (Papp) from apical-to-basolateral side (A–B)
was similar to that from basolateral-to-apical side (B–A)
(Fig. 3). For (+)-thalidomide the Papp values (cm/s)
were 6.89·105 and 5.70·105, for ()-thalidomide
6.90·105 and 5.67·105, respectively. There was a
trend towards increased A–B transport, however it was
not statistically signiﬁcant (p > 0.1). The enantiomers
showed no diﬀerences in their permeability. The ratios
Papp (B–A) over Papp (A–B), as a measure for active
transport, were 0.826 and 0.822 for (+)- and ()-tha-
lidomide, respectively. Dose-dependent transport of 10,
50, 100, and 250 lM thalidomide after 10 min appeared
to be linear. The correlation coeﬃcients were > 0.999
for both enantiomers (Fig. 4).
Discussion
Drug transporters, such as P-glycoprotein, are increas-
ingly recognised as an important determinant of drug
disposition [24]. Like cytochrome P450 enzymes, inhi-
bition and induction of P-gp have been reported as the
cause of drug–drug interactions [20]. Here we showed
that the drug thalidomide is not capable of inhibiting P-
gp function or inducing its expression. This knowledge
may be of importance, because thalidomide is a drug
that is increasingly used in clinical studies, mainly as an
adjuvant therapy.
Fig. 1 Expression of MDR1 in
LS180 cells. Cells were
incubated for 72 h. Rifampicin







P-gp expression has been shown to be inducible by
many xenobiotics such as rifampicin [25], phenobarbital
[26], dexamethasone [27], and herbal extracts from St.
John’s wort [28, 29]. In this study, we used the LS180 cell
line as an appropriate model to investigate P-gp induc-
tion. LS180 cells are derived from a human colon car-
cinoma cell line and it has been shown that several drugs
such as rifampicin or phenobarbital could increase P-gp
mRNA and protein content in these cells [30, 31]. Rif-
ampicin, used as positive control in our experiments,
strongly induced MDR1 expression, whereas thalido-
mide did not change MDR1 mRNA levels.
Several cases of drug–drug interactions caused by
P-gp inhibition have been reported. Elevated digoxin
plasma concentrations were observed with cardiac drugs
that are P-gp inhibitors such as verapamil or quinidine
[32, 33]. Ketoconazole, a potent P-gp inhibitor, caused a
marked increase in the CSF concentration of ritonavir
and saquinavir [34]. By measuring the rhodamine 123
uptake in a cell line over-expressing MDR1, we used a
Fig. 2 Uptake of R123 in
CCRF/MDR1 cells. Verapamil
(100 lM) was applied as a P-gp
inhibitor. Values represent
mean intracellular R123
ﬂuorescence±SEM; N = 4
Fig. 3 Apparent permeability
(Papp) of (±)-thalidomide
(100 lM) through Caco-2 cells.
The drug was added to the
basolateral side (B–A) or to the
apical side (A–B) of the
monolayers. Values represent
mean±SEM; N = 3.
Diﬀerences are not signiﬁcant
(p > 0.05)
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speciﬁc assay for the investigation of functional P-gp
inhibition. Though this assay is not able to discriminate
between substrates and inhibitors, it can be concluded
that thalidomide does not interact with P-gp, neither as
a substrate nor as an inhibitor. Verapamil, a known P-
gp inhibitor in vitro and in vivo, was used as a positive
control showing signiﬁcant accumulation of rhodamine
123 in the cells.
At present, it is unclear whether transporters are in-
volved in the absorption of thalidomide. We determined
the bi-directional permeability and the dose-dependent
transport of thalidomide enantiomers through Caco-2
cell monolayers. This cell line is generally accepted as
in vitro model to study intestinal permeation [35]. Fur-
thermore, Caco-2 cells are reported to express mem-
brane transporters, such as P-gp and multi-drug
associated proteins (MRPs) [30, 36]. Therefore, we used
this model to assess if thalidomide underwent carrier-
mediated transport and whether there is a diﬀerence in
the permeability between (+)- and ()-thalidomide. The
ratio Papp (B to A) over Papp (A to B) is a measure for
active, apical directed transport. For paclitaxel, a known
P-gp substrate, this ratio was reported to be 41.9 in
Caco-2 cells [37]. For thalidomide, we observed equal
transport for both directions of the monolayer leading
to a Papp ratio of 0.82. In a previous study, where tha-
lidomide transport through Caco-2 cells was also
investigated, similar results were obtained [38]. In addi-
tion, they showed that verapamil had no eﬀect on tha-
lidomide permeability. A drawback of their study,
however, was the lack of chiral separation. The present
study is the ﬁrst one investigating the transepithelial
transport of thalidomide including chiral separation of
the enantiomers.
Due to the fast chiral inversion at physiological pH,
the stereoselective absorption of thalidomide can hardly
be determined in vivo. In order to avoid racemisation,




monolayers. 10, 50, 100, and
250 lM (±)-thalidomide were
added to the apical
compartment. After 10 min the
transported amounts (n moles)
of (+)- and ()-thalidomide
were determined. Values
represent means±SEM; N = 3
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acidiﬁed when drawn from the acceptor chamber [23].
Since both enantiomers share the same physical and
chemical properties, diﬀerent absorption rates could
indicate an interaction of thalidomide with chiral
structures such as proteins. Our results show, however,
that there is no diﬀerence in the permeability of the
enantiomers.
In conclusion, thalidomide exhibited no functional
interaction with P-gp in our in vitro experiments. Fur-
thermore, thalidomide did not induce P-gp expression.
Drug–drug interactions due to these mechanisms are
therefore unlikely. Transport studies showed linear
permeability that appeared to be neither site-directed
nor stereoselective. These results suggest that passive
diﬀusion is predominantly involved in thalidomide
absorption. Luminal eﬄux pumps like P-gp seem not to
restrict oral thalidomide uptake, which could also ex-
plain the high bioavailability found in vivo. Moreover,
the eﬃcacy of thalidomide in cancer therapy is most
likely not limited by P-gp over-expression in tumour
tissues. Whether thalidomide has an aﬃnity to other
transporters cannot be ruled out by this study and fur-
ther investigations are required.
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